#CLPT

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe Click here to read more

1 month ago

#ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe - Read more here: https://loom.ly/EfJuDX0
#CLPT

0 0 0 0

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe ClearPoint Neuro (NASDAQ:CLPT) announced EU MDR certification (CE mark) for ClearPoint Navigation Software Version 3.0.2, making the release available in Europe and unifying the US and EU navigation platforms.Version 3.0.2 adds an intraoperative CT workflow and compatibility with intraoperative CT and cone-beam CT, extending navigation from MRI-only to operating room use when paired with the SmartFrame XG stereotactic frame. The company cited prior FDA clearance of ClearPoint 3.x 11 months earlier and said most US customers have adopted the software.

1 month ago

#CLPT ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

1 month ago

#ClearPoint Neuro was excited to take part in the recent #BIG10 Neurosurgery Research Consortium. Our new Chief Medical Officer - Dr. Paul Larson - got a chance to share his vision for advancing our Biologics and Drug Delivery development programs. #CLPT

0 0 0 0

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue ClearPoint Neuro (Nasdaq:CLPT) reported preliminary unaudited Q4 2025 revenue of ~$10.4M, representing 20% comparable sales growth versus Q4 2024; IRRAflow product sales were only partially included after a recent acquisition. Full-year 2025 revenue was approximately $37M. Management expects 2026 total revenues of $54M–$60M, driven by organic growth and completion of IRRAflow integration. Segment trends in Q4 included functional neurosurgery disposables (+23%) and biologics/drug delivery (+26%). Results are preliminary and unaudited; audited financials and a Form 10-K will be filed in Q1 2026. Management will meet investors at the J.P. Morgan Healthcare Conference on January 12–13, 2026.

2 months ago

#CLPT ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

ClearPoint Neuro Completes Acquisition of IRRAS ClearPoint Neuro (Nasdaq:CLPT) completed its acquisition of IRRAS on November 20, 2025. Consideration included $5.0 million cash and 1,325,000 shares of ClearPoint common stock, plus a revenue share on certain IRRAS products for defined periods. IRRAS brings the IRRAflow active fluid-exchange system, more than 50 active customers, and an expanded commercial team. IRRAS results will be consolidated into ClearPoint's financials starting in Q4 2025. Management highlighted expected commercial scale and strategic fit with ClearPoint’s neuro drug-delivery platform.

3 months ago

#CLPT ClearPoint Neuro Completes Acquisition of IRRAS

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

ClearPoint Neuro Reports Third Quarter 2025 Results Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later CommercializationSOLANA BEACH, CA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell,

4 months ago

#CLPT ClearPoint Neuro Reports Third Quarter 2025 Results

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

ClearPoint Neuro Announces Agreement to Acquire IRRAS ClearPoint Neuro (Nasdaq:CLPT) announced an agreement to acquire IRRAS, maker of the FDA-cleared and CE-marked IRRAflow intracranial fluid management system. Consideration at closing: $5.0M cash plus 1,325,000 ClearPoint shares, plus a revenue‑share on certain IRRAS products. IRRAS brings >50 active customers, 10 patent families, an estimated $9.0M 2025 revenue run‑rate (83% growth in first 9 months of 2025), and ~40 commercial staff.Management expects combined 2026 revenue of $54.0M–$60.0M. Closing is subject to IRRAS shareholder approval and customary conditions; deal expected in Q4 2025.

4 months ago

#CLPT ClearPoint Neuro Announces Agreement to Acquire IRRAS

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

4 months ago

We always appreciate the invitation to participate in the #ASSFN Stereotactic & Functional Neurosurgery Hands-on Course @ University of Colorado Anschutz. This year marks the debut of #ClearPoint’s new iCT-guidance option & 1.5T labeling for the #Prism Laser Therapy System. #CLPT

0 0 0 0

4 months ago

#ClearPoint has been named 1 of America’s Growth Leaders by TIME! This recognition highlights the growing impact of our team & products. Several key programs are converging to drive an increasing global impact, & we’re excited to see what’s next! #CLPT
https://loom.ly/NuC_f2o

0 0 0 0

5 months ago

It’s been another great #ESGCT meeting, and there’s still time to catch up with the #ClearPoint team at Booth C03 tomorrow. If you didn’t make it to the conference, we’re always available for an online meeting! #ESGCT2025 #CLPT

0 0 0 0

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles Read More Here

5 months ago

#ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles at Booth 545 - Read More Here: https://loom.ly/Fv4xNnk
#2025CNS #CLPT #LITT #LaserTherapy #Glioblastoma #NeuroOncology #MedTech

0 0 0 0

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne

5 months ago

#CLPT ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

5 months ago

Doctor holding a digital globe with connected network nodes, symbolizing ClearPoint Neuro’s global medical technology reach.

(NASDAQ: #CLPT)
#ClearPoint Neuro secures new regulatory approvals in Canada, Hong Kong, and Taiwan—now reaching 34 countries. This global expansion boosts its support for 60+ BioPharma partners and drives growth in cell and gene therapy delivery.
prismmarketview.com/clearpoint-e...

0 0 0 0

ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide ClearPoint Neuro (NASDAQ:CLPT) announced expanded regulatory clearances for its therapy delivery products in Canada, Hong Kong, and Taiwan, bringing total cleared countries to 34. The company said these clearances are intended to simplify regional clinical trial design and support BioPharma partners' paths toward global commercialization. ClearPoint noted it works with 60+ BioPharma sponsors and will demonstrate US-cleared products at the CNS Annual Congress, Oct 13–15, 2025. The release also highlights the SmartFlow Neuro Cannula 510(k) FDA clearance for CSF aspiration, intraventricular Cytarabine injection, and delivery of gene therapy KEBILIDI to brain parenchyma.

5 months ago

#CLPT ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

5 months ago

Join our Biologics team this week at Booth C03 in Seville, Spain for #ESGCT to hear about our latest innovations and how #ClearPoint is leading the way for delivery of gene and cell therapies from discovery to commercialization! #ESGCT2025 #CLPT

0 0 0 0

5 months ago

Breaking News: ( NASDAQ: #CLPT ) ClearPoint Neuro Inc. (NASDAQ: CLPT) Climbs to New 52-Week High

0 0 0 0

5 months ago

JUST IN: ( NASDAQ: #CLPT ) A RUM and AI, Please

0 0 0 0

ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System Read More Here

5 months ago

#ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System - Read More Here: https://loom.ly/D5GHYhQ
#CLPT

0 0 0 0

Revolutionary Robot-Guided Brain Navigation System: ClearPoint Neuro's New Platform for Gene Therapy Delivery ClearPoint Neuro develops proprietary robotic navigation system for precise brain drug delivery, combining KUKA LBR Med Robot with their navigation software. Demo planned for CNS Congress Oct 13-15.

5 months ago

#CLPT ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0

5 months ago

NEWS: ( NASDAQ: #CLPT ) ClearPoint Neuro Inc. (NASDAQ: CLPT) Sets New 52-Week High in Monday Session

0 0 0 0

5 months ago

#ClearPoint Neuro’s EMEA team is excited to support the European Society for Stereotactic & Functional #Neurosurgery in Budapest this week! If you're attending, stop by to say hello & learn about how we're supporting therapeutic delivery in a growing number of countries. #ESSFN2025 #CLPT

0 0 0 0

5 months ago

Just In: ( NASDAQ: #CLPT ) ClearPoint Neuro Inc. (NASDAQ: CLPT) Rises Sharply in 9/24 Early Trading Session

0 0 0 0

6 months ago

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners - Read More Here: https://loom.ly/_YPnPJc
#CLPT

0 0 0 0

60% More Hospitals Can Now Use ClearPoint's Brain Laser Therapy After Major FDA Clearance Expansion ClearPoint Prism Neuro Laser System now compatible with both 1.5T and 3T MRI scanners, expanding access to 60% of U.S. hospitals. Follows 70% Q1 growth in neurosurgery products.

6 months ago

#CLPT ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

www.stocktitan.net/news/CLPT/clear-point-ne...

0 0 0 0